IFI16 is downregulated in HER2+ BC cells via synergistic histone modification by EZH2 and histone deacetylase, inducing STING/CXCL10/11 immune signaling defects associated with HER2 monotherapy and HER2 treatment resistance (136, 137). This evidence concerns the gene IFI16 and breast cancer.